Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 4, Number 4—December 1998

Synopsis

Rotavirus

Umesh D. ParasharComments to Author , Joseph S. Bresee, Jon R. Gentsch, and Roger I. Glass
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table

Efficacy of the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) in clinical trials

Vaccine
efficacy (%)
Country (ref) Age of vaccinees No. enrolled vaccine/ placebo Vaccine dose (PFU) No. doses Circulating strains All disease Severe disease
Industrialized
Finland (42) 3-5 mo 1,191/1,207 4 x 105 3 G1,G2 68 61-100
United States (43) 5-25 wk 403/400 4 x 105 3 G1,G3 49 80-100
United States (44) 2-6 mo 347/348 4 x 105 3 G3 50 64
United States (45) 4-26 wk 332/330 4 x 104 3 G1,G3 57 82
Developing
Venezuela (41) 8-18 wk 1,112/1,095 4 x 105 3 G1 48 88
Peru (46) 2-4 mo 219/209 4 x 104 3 G1,G2 24 0-40
Brazil (47) 1-5 mo 233/233 4 x 104 3 G1,G2 35 46

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO